Eli Lilly just announced phase 3 clinical trial results for its new medication, retatrutide, and it could become the most ...

Eli Lilly ( LLY 2.00%) recently announced stellar results from a phase 3 clinical trial, Triumph-4, which evaluated efficacy ...

Eli Lilly is leading the market for GLP-1 medications (for weight loss and diabetes). In a decade, Eli Lilly could be in the ...

Discover why Eli Lilly and Company's retatrutide weight loss breakthrough positions LLY as a leader in obesity therapeutics.

Step aside, semaglutide—retatrutide is showing the most impressive weight loss results of any obesity drug to date.

Eli Lilly said its next generation weight-loss drug retatrutide resulted in significant weight loss and reduced knee pain in ...

The maker of Zepbound reported results from a study of retatrutide, which targets three hormones in the body and led to much more weight loss than any approved drug.

Are you familiar with the term “triple agonist”? If you aren’t now, it might be one to file away for later use, in much the ...

Orforglipron is Eli Lilly’s weight-loss pill, and Bank of America expects it to enter the market in the second half of 2026 ...

Eli Lilly’s latest weight-loss shot helped patients lose as much as 29 per cent of their body weight in trials, giving ...

In an added benefit, more than one in eight people taking the highest dose of Retratrutide were completely free of arthritic ...